KHN922 not checked
Chengdu Kanghong Biotech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens,intravenous (IV) administration every three weeks (D1) .”In the company’s words, NCT07514975 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumors Cancer
- Main trialPhase 1/2
- “A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors”In the company’s words, NCT07514975 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumors Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | Apr 2028 | First-In-Human Study of KHN922 for Injection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026